Skip to main content

Table 2 Clinical Activity of Avelumab in Thymic Epithelial Tumors

From: Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Patient Number WHO Histology Treatment Dose (mg/kg) Best Response Number of Doses Duration of Response (weeks)
1 B3 thymoma 20 cPR 1 14
2 B3 thymoma 20 SD 3
3 B2 thymoma 20 uPR 1 17
4 Thymic carcinoma 10 SD 8
5 B2 thymoma 10 SD 18
6 B2 thymoma 10 uPR 1 4
7 B3 thymoma 10 PD 6
8 B1 thymoma 10 cPR 10 12
  1. cPR confirmed partial response, SD stable disease, uPR unconfirmed partial response, PD progressive disease